Sun Pharma and Philogen sign global licensing agreement for anti-cancer immunotherapy Fibromun, enhancing Sun Pharma's oncology portfolio.

Sun Pharmaceutical Industries and Philogen S.p.A. have signed a global licensing agreement for Fibromun, an anti-cancer immunotherapy targeting soft tissue sarcoma and glioblastoma. Sun Pharma gains exclusive worldwide commercialization rights, while Philogen will conduct ongoing clinical trials and pursue regulatory approval. Revenue sharing is set at 45% for Philogen and 55% for Sun Pharma. This partnership enhances Sun Pharma's oncology portfolio.

October 01, 2024
13 Articles